Bifidobacterium breve is one of the predominant species in the infant gut and are widely recognized for its beneficial roles in maintaining infant health. B. breve M-16V has emerged as one of the best studied clinically effective probiotic strains that exert positive effects, particularly in infants, to support healthy growth and promote well-being.

Bifidobacterium longum subsp. longum BB536 is one of the most well-established, clinically effective probiotic strains that confers numerous profound beneficial effects on humans. BB536 possesses a proven track record of safety and clinical efficacy in improving gastrointestinal, immunological and infectious conditions, as demonstrated in more than 180 scientific studies.

Bifidobacterium breve B-3 is an unique probiotic strain, developed by focusing on the relationship between gut microbiota and metabolic syndrome. B-3 possesses an attractive effect in maintaining healthy body weight and ultimately improving one’s lifestyle.

Bifidobacterium longum subsp. infantis M-63 is unique among gut bacteria in its immense capacity to utilize human milk oligosaccharide (HMOs), the component that is highly abundant in human breast milk. HMOs offer no direct nutritive value for infants, but they function in shaping the infant intestinal microbiota with life-long impacts.